|
|
Blood, 1 February 2006, Vol. 107, No. 3, pp. 862-869.
Prepublished online as a Blood First Edition Paper on October 18, 2005; DOI 10.1182/blood-2005-07-2702.
 Previous Article | Table of Contents | Next Article 
REVIEW ARTICLES
Epstein-Barr virus: the impact of scientific advances on clinical practice
Hilary Williams, and
Dorothy H. Crawford
From the Department of Oncology, Bristol Royal Infirmary, Bristol, United Kingdom; and the Basic and Clinical Virology Laboratory, Centre for Infectious Diseases, University of Edinburgh, Edinburgh, United Kingdom.
Epstein-Barr virus (EBV) is a tumorigenic herpes virus that infects and persists in B lymphocytes in the majority of humans, generally without causing disease. However, in a few individuals the virus is associated with significant pathology, particularly benign and malignant lymphoproliferations. Recently acquired knowledge on the mechanisms of EBV persistence, immune control of primary and persistent infection, and disease pathogenesis is now being translated into the clinic with novel methods of diagnosis, prevention and treatment contributing to improved patient care. This review concentrates on these recent advances in the field of hematology/oncology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Wiedmer, P. Wang, J. Zhou, A. J. Rennekamp, V. Tiranti, M. Zeviani, and P. M. Lieberman
Epstein-Barr Virus Immediate-Early Protein Zta Co-Opts Mitochondrial Single-Stranded DNA Binding Protein To Promote Viral and Inhibit Mitochondrial DNA Replication
J. Virol.,
May 1, 2008;
82(9):
4647 - 4655.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Liu, H.-E. Claesson, Y. Mahshid, G. Klein, and E. Klein
Leukotriene B4 activates T cells that inhibit B-cell proliferation in EBV-infected cord blood-derived mononuclear cell cultures
Blood,
March 1, 2008;
111(5):
2693 - 2703.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Scheinberg, S. H. Fischer, L. Li, O. Nunez, C. O. Wu, E. M. Sloand, J. I. Cohen, N. S. Young, and A. John Barrett
Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia
Blood,
April 15, 2007;
109(8):
3219 - 3224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Dong, Y. Masaki, T. Takegami, T. Kawanami, K. Itoh, Z.-X. Jin, C.-R. Huang, X.-P. Tong, T. Fukushima, M. Tanaka, et al.
Cloning and expression of two human recombinant monoclonal Fab fragments specific for EBV viral capsid antigen
Int. Immunol.,
March 1, 2007;
19(3):
331 - 336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Savoldo, J. A. Goss, M. M. Hammer, L. Zhang, T. Lopez, A. P. Gee, Y.-F. Lin, R. E. Quiros-Tejeira, P. Reinke, S. Schubert, et al.
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)
Blood,
November 1, 2006;
108(9):
2942 - 2949.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Lemas and R. F. Ambinder
The kiss that scars
Blood,
July 1, 2006;
108(1):
8 - 8.
[Full Text]
[PDF]
|
|
|
| |
